• Login
    View Item 
    •   MBRU Knowledge Repository Home
    • College of Medicine (CoM)
    • Faculty Publications (CoM)
    • View Item
    •   MBRU Knowledge Repository Home
    • College of Medicine (CoM)
    • Faculty Publications (CoM)
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic E ect

    View/Open
    204-2020.63 Yajnavalka Banerjee.pdf (521.5Kb)
    Date
    2020
    Author
    Banerjee, Yajnavalka
    Metadata
    Show full item record
    Abstract
    Abstract: Liraglutide has shown favourable e_ects on several cardiometabolic risk factors, beyond glucose control. MicroRNAs (miRNAs) regulate gene expression, resulting in post-transcriptional modifications of cell response and function. Specific miRNAs, including miRNA-27b, miRNA-130a, and miRNA-210, play a role in cardiometabolic disease. We aimed to determine the e_ect of liraglutide on the serum levels of miRNA-27b, miRNA-130a and miRNA-210. Twenty-five subjects with type-2 diabetes mellitus (T2DM), naïve to incretin-based therapy, were treated with liraglutide (1.2 mg/day as an add-on to metformin) for 4 months. miRNAs were quantified using real-time polymerase chain reaction. After liraglutide treatment, we found significant reductions in fasting glucose (from 9.8 _ 5.3 to 6.7 _ 1.6 mmol/L, p = 0.0042), glycosylated haemoglobin (HbA1c) (from 8.1 _ 0.8 to 6.6 _ 1.0%, p = 0.0008), total cholesterol (from 5.0 _ 1.0 to 4.0 _ 0.7 mmol/L, p = 0.0011), triglycerides (from 1.9 _ 1.0 to 1.5 _ 0.8 mmol/L, p = 0.0104) and low-density lipoprotein cholesterol (from 2.9 _ 1.2 to 2.2 _ 0.6 mmol/L, p = 0.0125), while the serum levels of miRNA-27b, miRNA-130a and miRNA-210a were significantly increased (median (interquartile range, IQR) changes: 1.73 (7.12) (p = 0.0401), 1.91 (3.64) (p = 0.0401) and 2.09 (11.0) (p = 0.0486), respectively). Since the changes in miRNAs were independent of changes in all the metabolic parameters investigated, liraglutide seems to exert a direct epigenetic e_ect in T2DM patients, regulating microRNAs involved in the maintenance of endothelial cell homeostasis. These changes might be implicated in liraglutide’s benefits and may represent useful targets for cardiometabolic management.
    URI
    https://repository.mbru.ac.ae/handle/1/364
    Collections
    • Faculty Publications (CoM)

    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback
    Theme by 
    Atmire NV
     

     

    Browse

    All of MBRU Knowledge RepositoryCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback
    Theme by 
    Atmire NV